v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]        
Revenues $ 33,088 $ 22,842 $ 58,950 $ 40,855
Cost of revenues [1] 7,351 3,968 13,277 7,811
Research and development [1] 9,710 6,131 16,964 11,356
Sales and marketing [1] 14,320 8,105 24,671 14,677
General and administrative [1] 9,955 4,200 21,410 6,579
Depreciation and amortization 926 149 1,599 331
Operating (loss) profit (9,174) 289 (18,971) 101
Finance expenses (income), net (13,306) 1,602 (15,617) 3,171
Profit (loss) before taxes 4,132 (1,313) (3,354) (3,070)
Taxes on income (tax benefit) (168) 346 (205) 525
Net profit (loss) 4,300 (1,659) (3,149) (3,595)
Accretion of preferred stock to redemption value 0 (21,076) 0 (44,804)
Net loss attributable to common stockholders, basic 4,300 (22,735) (3,149) (48,399)
Net loss attributable to common stockholders, diluted $ 4,300 $ (22,735) $ (3,149) $ (48,399)
Net loss per stock attributable to common stockholders        
Basic (in dollars per share) [2] $ 0.03 $ (1.33) $ (0.02) $ (2.85)
Diluted (in dollars per share) [2] $ 0.03 $ (1.33) $ (0.02) $ (2.85)
Weighted-average number of stocks used in computing net loss per stock attributable to common stockholders        
Basic (in shares) [2] 132,152,652 17,116,586 128,220,893 16,956,139
Diluted (in shares) [2] 139,988,123 17,116,586 128,220,893 16,956,139
[1] Exclusive of depreciation and amortization presented separately.
[2] Prior period results have been adjusted to reflect the exchange of Innovid Inc’s common stock for Innovid Corp’s common stock at an exchange ratio of approximately 1.337 as a result of the Transaction. See Note 3 for further details.

Source